Novavax's stock surged 5.02% in pre-market trading on Thursday, indicating strong investor interest ahead of the regular session.
The significant pre-market gain appears to be driven by a positive analyst action. TD Cowen raised its price target on Novavax to $9 from $8, while maintaining a Hold rating on the shares. Such upward revisions in price targets are often viewed by the market as a sign of improving fundamentals or prospects, prompting buying activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments